Jiangxi Xihong Biomedicine

Jiangxi Xihong Biomedicine is a clinical-stage biotechnology company focused on developing innovative small molecule drugs for oncology. The company's lead program, XH-101, is a highly selective USP1 inhibitor currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, including ovarian and breast cancers. Headquartered in Nanchang with R&D operations in Shanghai, Xihong Biomedicine utilizes its medicinal chemistry expertise to target the DNA damage response (DDR) pathway. The company is supported by prominent regional investors, including Jiangxi Gan-Chuang and Nanchang Industrial Investment. Xihong Biomedicine aims to address significant unmet medical needs in the global cancer market through its pipeline of targeted therapies. The firm maintains a strong focus on translational medicine to accelerate the development of its proprietary candidates.